These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11998714)

  • 21. Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan.
    Kühne A; Kaiser R; Schirmer M; Heider U; Muhlke S; Niere W; Overbeck T; Hohloch K; Trümper L; Sezer O; Brockmöller J
    Pharmacogenet Genomics; 2007 Jul; 17(7):505-17. PubMed ID: 17558306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacogenetics of anticancer drugs].
    de Chaisemartin L; Loriot MA
    Pathol Biol (Paris); 2005 Mar; 53(2):116-24. PubMed ID: 15708657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Individual susceptibility to occupational carcinogens: the evidence from biomonitoring and molecular epidemiology studies].
    Pavanello S; Clonfero E
    G Ital Med Lav Ergon; 2004; 26(4):311-21. PubMed ID: 15584438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case-control study in a Southern Italian population.
    Improta G; Sgambato A; Bianchino G; Zupa A; Grieco V; La Torre G; Traficante A; Cittadini A
    Anticancer Res; 2008; 28(5B):2941-6. PubMed ID: 19031937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents).
    Brent RL
    Pediatrics; 2004 Apr; 113(4 Suppl):984-95. PubMed ID: 15060191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic polymorphisms in assessing interindividual variability in delivered dose.
    Haber LT; Maier A; Gentry PR; Clewell HJ; Dourson ML
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):177-97. PubMed ID: 12052003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms in DNA repair genes and associations with cancer risk.
    Goode EL; Ulrich CM; Potter JD
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1513-30. PubMed ID: 12496039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The managed immune system: protecting the womb to delay the tomb.
    Dietert RR; Piepenbrink MS
    Hum Exp Toxicol; 2008 Feb; 27(2):129-34. PubMed ID: 18480137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of molecular genetics in the pathogenesis and diagnosis of neonatal sepsis.
    Del Vecchio A; Laforgia N; Capasso M; Iolascon A; Latini G
    Clin Perinatol; 2004 Mar; 31(1):53-67. PubMed ID: 15183656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of drug transporter studies on drug discovery and development.
    Mizuno N; Niwa T; Yotsumoto Y; Sugiyama Y
    Pharmacol Rev; 2003 Sep; 55(3):425-61. PubMed ID: 12869659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
    Gómez-Lechón MJ; Castell JV; Donato MT
    Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
    Zwaveling J; Press RR; Bredius RG; van Derstraaten TR; den Hartigh J; Bartelink IH; Boelens JJ; Guchelaar HJ
    Ther Drug Monit; 2008 Aug; 30(4):504-10. PubMed ID: 18641537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Host susceptibility in organic solvent toxicity.
    Pelkonen O
    Prog Clin Biol Res; 1986; 220():107-14. PubMed ID: 3797432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic failure: importance of genes?].
    Lhermitte M; Allorge D; Broly F
    Ann Pharm Fr; 2006 Nov; 64(6):406-15. PubMed ID: 17119471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Side effects of antibiotics: which patients are at risk?
    Dash CH
    Mod Med Asia; 1978 Nov; 14(11):8-10. PubMed ID: 723848
    [No Abstract]   [Full Text] [Related]  

  • 37. [Main factors of variations in lidocaine pharmacokinetics].
    Bruguerolle B; Valli M; Jadot G; Bouyard P
    Therapie; 1983; 38(1):27-38. PubMed ID: 6346570
    [No Abstract]   [Full Text] [Related]  

  • 38. Human variability and noncancer risk assessment--an analysis of the default uncertainty factor.
    Renwick AG; Lazarus NR
    Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 1):3-20. PubMed ID: 9629592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro screening for population variability in chemical toxicity.
    O'Shea SH; Schwarz J; Kosyk O; Ross PK; Ha MJ; Wright FA; Rusyn I
    Toxicol Sci; 2011 Feb; 119(2):398-407. PubMed ID: 20952501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential sensitivity of children and adults to chemical toxicity. II. Risk and regulation.
    Dourson M; Charnley G; Scheuplein R
    Regul Toxicol Pharmacol; 2002 Jun; 35(3):448-67. PubMed ID: 12202058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.